Full Press Release Details
Fresenius Medical Care published form 20-F for the fiscal year
Fresenius Medical Care, the world's leading
provider of products and services for individuals with renal diseases, has filed the annual report 2021 on form 20-F with the U.S. Securities
and Exchange Commission (SEC). The report is available at the company's website (freseniusmedicalcare.com) in the "Investors"
section as well as at the SEC's website (www.sec.gov).
A hard copy of Fresenius Medical Care's
annual report on form 20-F including the complete audited financial statements may be obtained from the company free of charge upon request
to the company's Investor Relations department by email at ir@fmc-ag.com.
The company also published a Facts & Figures 2021 website at www.factsandfigures.freseniusmedicalcare.com
to provide an overview of the key financial figures for the fiscal year 2021. In addition, the new Corporate Magazine, Company Profile
as well as a Five-Year-Summary are available for download.
Fresenius Medical Care is the world's leading
provider of products and services for individuals with renal diseases of which around 3.8 million patients worldwide regularly undergo
dialysis treatment. Through its network of 4,171 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately
345,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines
or dialyzers. Along with its core business, the Renal Care Continuum, the Company focuses on expanding in complementary areas and in the
field of critical care. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the Company's website at www.freseniusmedicalcare.com.
This release contains forward-looking statements
that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking
statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes,
regulatory approvals, impacts related to COVID-19, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation
or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical
Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does
not undertake any responsibility to update the forward-looking statements in this release.